Duration of Device-Based Fever Prevention after Cardiac Arrest.

Christian HassagerHenrik SchmidtJacob E MøllerJohannes GrandSimon MølstrømRasmus P BeskeSøren BoesgaardBritt BorregaardDitte Bekker-JensenJordi S DahlMartin S FrydlandDan E HøfstenYusuf A IsseJakob JosiassenVibeke R Lind JørgensenDaniel KondziellaMatias G LindholmEmil MoserBenjamin C NyholmLaust E R OblingLaura SarkisianFrederik T SøndergaardJakob H ThomsenJens J ThuneSøren VenøSebastian C WibergMatilde Winther-JensenMartin Abild Stengaard MeyerJesper Kjaergaard

Published in: The New England journal of medicine (2022)

Active device-based fever prevention for 36 or 72 hours after cardiac arrest did not result in significantly different percentages of patients dying or having severe disability or coma. (Funded by the Novo Nordisk Foundation; BOX ClinicalTrials.gov number, NCT03141099.).

Keyphrases

cardiac arrest
cardiopulmonary resuscitation
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
multiple sclerosis
palliative care
prognostic factors